Correlation Analyses of Imetelstat Exposure with PharmacodynamicE ect, E icacy and Safety… Par MarcGuevreguian|2021-03-22T19:47:48+01:00novembre 5th, 2020| Lire la suite
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study Par MarcGuevreguian|2021-03-22T20:58:56+01:00octobre 27th, 2020| Lire la suite
Benefits of molecular profiling with next-generation sequencing… Par MarcGuevreguian|2021-03-22T19:48:15+01:00septembre 26th, 2020| Lire la suite
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans Par MarcGuevreguian|2021-03-22T19:13:50+01:00septembre 18th, 2020| Lire la suite
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups Par MarcGuevreguian|2021-03-22T20:51:59+01:00août 15th, 2020| Lire la suite
Molecular profiling and risk classification of patients… Par MarcGuevreguian|2021-03-22T20:28:00+01:00août 11th, 2020| Lire la suite
Spliceosome mutations are common in persons with myeloproliferative neoplasm… Par MarcGuevreguian|2021-03-22T21:04:06+01:00août 7th, 2020| Lire la suite
Long-term efficacy and safety of ruxolitinib in polycythaemia vera – Authors’ reply Par MarcGuevreguian|2021-03-22T19:58:11+01:00juillet 22nd, 2020| Lire la suite
Long-term follow-up of JAK2 exon 12 polycythemia vera Par MarcGuevreguian|2021-03-22T20:23:18+01:00juillet 21st, 2020| Lire la suite
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib… Par MarcGuevreguian|2021-03-22T19:49:02+01:00juillet 15th, 2020| Lire la suite
